Introduction
In recent years the management of inflammatory bowel diseases (IBD) has substantially changed, due to the fact that the new treatments with anti-TNF␣ drugs induce not only clinical remission but also a significant endoscopic improvement, or even a total disappearance of the intestinal lesions [1] . Although conventional therapies with 5-aminosalicylic acid (5-ASA), oral steroids and immunomodulators may lead to mucosal healing (MH), the MH rate with these agents is lower than that obtained with anti-TNF␣ [2] [3] [4] [5] [6] [7] . At present, there is significant evidence that the use of anti-TNF␣ drugs, such as infliximab, adalimumab, and certolizumab pegol, can induce and sustain endoscopic healing [8, 9] . The mechanisms of action of the anti-TNF␣ therapies are largely unknown. Very recently, in 2 in vivo models Fischer found that adalimumab prevents intestinal barrier dysfunction and antagonises distinct effects of TNF on tight junction proteins and signalling pathways in intestinal epithelial cells. All these events may therefore represent a novel mechanism of action whereby antiTNF drugs participate in epithelial and tissue repair in CD and UC [10] .
MH has now become an important endpoint to assess the therapeutic effect in IBD [11] [12] [13] . The definition of MH currently used in CD and UC clinical trials is the "complete absence of all inflammatory and ulcerative lesions", but this definition lacks validation and does not include mucosal improvement and grading of MH [11, [14] [15] [16] . Furthermore, in most studies the definition of MH in UC includes the presence of "persistent erythema and friability at endoscopy" without ulceration or erosions [14] .
The aim of this paper is to review different definitions of endoscopic healing and to describe the endoscopic indices commonly used in clinical trials. We also point out the role of histological assessment and the need to use a standardised validated endoscopic score to avoid differences in MH rates among the various trials.
Controversies in MH definition
Controversies regarding the currently available definitions of MH are shown in Tables 1 and 2, reporting endoscopic indices, endoscopic features, MH definition, time/weeks between endoscopic re-evaluations and the percentage of patients showing MH. The different definitions of MH, such as "absence of ulcers" or "endoscopic scores improvement", as well as the duration of the biological therapy certainly interfere with the rate of MH. In fact, in CD patients the short-term re-evaluation at 10 weeks demonstrated an "absence of ulcers" ranging between 11% and 29% of patients, and this rate rose to 45%, 44%, and 73% when patients underwent endoscopy at 24-54 and 104 weeks. Instead, when MH was considered as an "endoscopic scores improvement", the shortterm MH rate at endoscopic re-evaluation ranged between 64% and 90% and remained at the same rate after medium and long-term treatment. In UC patients, the endoscopic short-term re-evaluation revealed a diagnosis of MH as "absence of ulcers" (MAYO 0) in about 27% of the patients, on the contrary when MH was considered as the "endoscopic scores improvement" (MAYO 1) the rate of MH ranged between 30% and 62% both in short-and long-term endoscopic re-evaluations.
The importance of achieving MH in clinical practice is correlated to recent evidence that shows that MH is associated with long-term symptomatic remission and a longer relapse-free interval [17] , as well as with a reduction in the frequency of hospitalizations, complications and surgical resections [18] [19] [20] , and with a significant improvement of quality of life [21] . Furthermore, MH is associated to a reduction of cancer risk and cancer-related mortality; data suggest that colorectal cancer in IBD patients is driven by a persistent active inflammation. Controlled prospective studies are lacking but a large cohort study indicates a lower risk of colorectal cancer in the presence of MH in patients treated with azathioprine [22] and infliximab [23] . All these events seem to have a prognostic relevance, but the role of MH in preventing progression and changing the natural history of IBD has never been demonstrated [24] probably due to the late use of anti-TNF drugs. 
Role of endoscopy
Ileocolonoscopy in IBD patients is used to: (i) diagnose CD and UC; (ii) predict an aggressive course of disease; (iii) obtain biopsies of the intestinal mucosa for histological examination; (iv) monitor dysplasia and the risk of colorectal cancer [25] . In the last few years a new important role of ileocolonoscopy has emerged in the evaluation of the mucosal response to therapy, i.e. the grade of MH.
Correlations between histological disease activity and endoscopy are fairly good, especially when the samples are obtained during active inflammation, even though microscopic features of activity may persist in a macroscopically inactive disease [26] . Modern sophisticated techniques, such as confocal laser endomicroscopy (CLE) and chromoendoscopy (CE), have been proposed to provide a more detailed view of the mucosa [27, 28] for assessing mucosal and histological healing and for the detection of intraepithelial neoplasia [29] . The potential role of CLE in the management of IBD patients is based on its capacity to evaluate, in vivo, the structural healing of chronic inflammation in IBD: crypt and vessel architecture, and cellular infiltration [30, 31] . Recently, a classification of activity inflammation in UC with CLE has been proposed [32] . The latest studies show that CLE images might offer information equivalent to conventional histology, with a good correlation between CLE and histological results. In particular, CLE is also able to assess MH after treatment with biological agents [33] and to predict disease outcome [34, 35] . Specific patterns observed with CE may be important for the identification of dysplasia during surveillance of UC [36] and CD patients [37] and for the diagnosis of intraepithelial neoplasia [38] . Neumann [39] recently developed an endomicroscopic activity index, denoted "Crohn's Disease Endomicroscopic Activity Score", to graduate the severity of inflammation in this disease. This score is the first endoscopic index for Crohn's disease based on in vivo histology, but its validity has still to be confirmed. The Watson score [40] is another scoring system based on functional in vivo imaging that may be used to predict clinical relapse. A clinical trial is now ongoing to analyse the mechanism of action of infliximab at the CLE level and to analyse MH, i.e. structural and functional changes in the mucosa in IBD patients [41].
Endoscopic scores in the era of MH
The need to evaluate MH has confirmed the function of endoscopy in the management and follow-up of IBD patients. For this reason, endoscopic scores used to classify disease activity [11, 12] have also been proposed to define MH in CD and UC. The main problem in the use of endoscopic scores is that many of these are complex and time-consuming. Another important limitation is the absence of: (a) a validated definition of MH; (b) guidelines for the correct and optimal timing of endoscopic re-evaluation during therapy; (c) agreement about cutoff values of endoscopic scores to measure MH and define endoscopic response or remission. Furthermore, the limited ability of conventional endoscopy to evaluate disease activity in the small bowel means that other tools are needed, such as capsule endoscopy or enteroscopy. The ECCO guidelines state that small bowel capsule endoscopy has an important role in the assessment of mucosal lesions or MH. However, also in this area there are no validated endoscopic indices to define remission and guide medical decision-making [42] .
Endoscopic scores in Crohn's disease
The first endoscopic score for evaluating the severity of ileocolonic lesions in CD was the Crohn's Disease Endoscopic Index of Severity (CDEIS), developed and validated by the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) in France [43] . This numerical score ranges between 0 and 44 and evaluates, in 5 bowel segments (terminal ileum, right colon, transverse, left colon and sigmoid, and rectum) on a 10-cm linear scale, the following features: (i) the presence or absence of ulcers, distinguished as superficial or deep; (ii) the presence of stenosis, classified as ulcerated or non-ulcerated; and (iii) the surface extension of disease activity, classified as ulceration or only inflammation. The score requires prior training but is highly reproducible among different operators. The time-consuming surface measurement technique (usually performed on previously recorded videos) is probably the main reason why CDEIS is only used in clinical trials and not in clinical practice. Recently, a new, simpler endoscopic score was developed by Daperno et al. [44] . This score, named "Simplified Endoscopic Activity Score for Crohn's Disease" (SES-CD), ranges from 0 to 60 and includes 4 variables: (i) the intestinal surface affected by ulcers; (ii) the intestinal surface affected by other inflammatory lesions; (iii) the presence of ulcers; (iv) the presence of narrowing (differentiated as single or multiple and permitting passage or not). Each of these variables is scored from 0 to 3 and evaluated in 5 intestinal segments (terminal ileum, right colon, transverse, left colon and sigmoid, and rectum). In this score the presence of ulcers is classified not as deep or superficial but according to size (0.1-0.5 cm; 0.5-2 cm; >2 cm), and ulcerated surfaces and intestinal surfaces affected by other inflammatory lesions are classified according to their extension (<10%; 10-30%; >30%); (<50%; 50-75%; >75%). A correlation between the SES-CD and the CDEIS [44] , and between the SES-CD and clinical and laboratory parameters [44] has been reported. Fig. 1 shows representative images (A, B, C) from different endoscopic scenarios induced by biological therapy in a CD patient.
In CD patients undergoing surgery, literature data demonstrate that disease recurrence is frequent and that 90% of patients have new endoscopic lesions as early as 1 year after surgery [45] . A validated endoscopic index (Rutgeert's score [46] ) measures endoscopic recurrence in the neo-terminal ileum and/or ileocolonic anastomosis. This score ranges from 0 to 4, classified as: (0) absence of lesions; (1) <5 aphthous lesions, (2) >5 more severe aphthous lesions; (3) diffuse inflammation with diffuse ulcers; (4) nodules and/or narrowing. The Rutgeert's score is the gold standard for the prognosis of postoperative recurrence; indeed, scores 3 and 4 are validated cutoff values that predict clinical relapse [47] . For this reason ileocolonoscopy is recommended within 1 year after surgical resection to orient treatment decision-making [48, 49] .
All the above endoscopic scores explore only the mucosal surface in CD but do not assess transmural injury and penetrating evolution, signs of progressive disease and structural bowel damage. Today, the important concept of "cumulative bowel damage" has emerged, and it has been included in a new index called "The Lemann score" (Crohn's Disease Digestive Damage Score). The Lemann score is a complex score that evaluates, in different gastrointestinal locations (upper gastrointestinal tract, small bowel, colon or rectum, and anal or perianal), strictures and penetrating lesions (ulceration, fistula, and abscess), as well as surgical resection or bypass of the bowel. Upper gastrointestinal endoscopy, colonoscopy, Computed Tomography Enterography (CTE) and Magnetic Resonance Imaging Enterography (MRE) are the methods used to assess transmural intestinal damage in the Lemman score. CTE and MRE visualise the precise site of intestinal lesions, mesenteric changes, and the presence of strictures, fistulae or abscesses, thus improving the detection of structural small bowel lesions. For each gastrointestinal segment, disease severity is scored from 0 (normal bowel with no history of surgery) to 3 (including progressive structural bowel lesions and resection). The Lemman score ranges from 0 (absence of damage) to 10 (complete resection of the gastrointestinal tract) [50] . This index has been developed to identify CD patients at high or low risk of rapid damage progression who would benefit from early biological treatment.
Endoscopic scores in UC
Numerous scores have been used for the assessment of endoscopic activity in UC. The first endoscopic score to evaluate disease activity in UC was proposed by Truelove and Witts [51] . With this score, the sigmoidoscopic appearance before and after corticosteroid treatment was classified on the basis of hyperaemia and mucosa granularity. In 1964, Baron [52] described endoscopic disease activity based only on the severity of bleeding and friability, while ulceration or other lesions were not considered. This score ranged from 0 to 4 and distinguished normal mucosa, abnormal but not haemorrhagic mucosa, moderately haemorrhagic mucosa with bleeding on contact, and severely haemorrhagic mucosa with spontaneous bleeding. The Powell-Tuck sigmoidoscopic score [53] and Sutherland score [54] , with ranges 0-2, focused on endoscopic evaluation only by assessing bleeding without considering the presence of other inflammatory lesions. Subsequent endoscopic indices have included the presence of erosions, mucopus, granularity, and ulcers. In the Rachmilewitz Endoscopic score [55] 4 items are included: vascular pattern, mucosal granularity, contact or spontaneous mucosal bleeding, and mucosal damage (mucus, fibrin, erosions and ulcer). This score ranges from 0 to 12. A cutoff value for remission is also defined. In a prospective study [56] a significant correlation between the Rachmilewitz Endoscopic score and clinical and laboratory activity indices was found, identifying the following cutoffs: (i) inactive disease with score 0-4; (ii) mild activity with score 4-6; (iii) moderate activity with score 7-9; (iv) high activity with score 10-12. To date, the Mayo sub-score [57] is the score system most widely used in clinical trials to describe the degree of endoscopic activity. The Mayo score is a composite index that includes 4 sub-scores: stool frequency, rectal bleeding, endoscopic findings, physician's global assessment. Each of these sub-scores ranges from 0 to 3, while the Mayo score ranges from 0 to 12. A score ≤2 means remission, 3-5 indicates mild disease, 6-10 indicates moderate disease, and 11-12 indicates severe disease. The Mayo endoscopic sub-score ranges from 0 to 3: (0) inactive disease and normal mucosa; (1) mild disease (erythema and mild friability); (2) moderate disease (marked erythema, absent vascular pattern, friability, erosions), (3) severe disease (spontaneous bleeding and diffuse ulceration). The limit of this score is that it does not distinguish between deep and superficial ulcerations. In clinical trials and practice, a Mayo endoscopic sub-score of 0 or 1 is a commonly accepted criterion for MH [14] and, as far as avoiding colectomy is concerned, it predicts a better outcome than a Mayo sub-score of 2-3. More recently, another score index has been proposed to measure endoscopic severity in UC. This score, named "Ulcerative Colitis Endoscopic Index of Severity" (UCEIS), includes 3 variables: (i) vascular pattern (normal = 1, patchy obliteration = 2; complete obliteration = 3); (ii) bleeding (none = 1, mucosal = 2, luminal mild = 3, luminal severe = 4); (iii) erosions and ulcers (none = 1, erosions = 2, superficial ulcers = 3, deep ulcers = 4) [58] . This score was developed as a validated index of endoscopic severity, although the sensitivity of the index to a specific change, and the threshold for MH, have yet to be determined. The correlations of this index need further investigation before its application in clinical trials and clinical practice.
Recently, the Ulcerative Colitis Colonoscopic Index of Severity (UCCIS) has been validated in a prospective cohort of UC patients [59] . This score is a composite index that includes 4 variables: vascular pattern, granularity, ulceration, bleeding/friability and severity of damage in each colon segment and overall. The global assessment of endoscopic severity is based on a 4-point scale and a 10-cm visual analogue scale. Table 1 summarises the endoscopic scores used in CD and UC. Fig. 1 shows representative images (D, E, F) of different endoscopic scenarios induced by biological therapy in a UC patient.
Histological features

Basic histopathological concepts
Like in other pathological conditions involving the large bowel, the pathologist should receive an adequate number of biopsies, correctly oriented from at least 5 sites (including the rectum and the terminal ileum). The biopsies should always be accompanied by a clinical report, including patient age, duration of the disease and duration and type of treatment [60] .
The diagnostic elements for histological assessment are: a) UC [61] : The diagnostic value of the histological features of UC and CD, and the differences between the 2 diseases have been extensively studied [63] . Crypt architectural abnormalities in the colon are more common in UC (57-100% of cases) than CD (27-71% of cases). Increased basal lamina propria cellularity and basal plasmacytosis are common in both UC and CD (76-92% and 72-81%, respectively). Crypt abscesses are more common in UC (41%) than CD (19%), while granulomas are characteristic of CD, being present in 21-37% of biopsy specimens [64] . Basal plasmacytosis is present in more than 50% of IBD patients [65] , in 38% of patients with symptoms for less than 2 weeks, and has disappeared in 50% of IBD patients without relapse, by 1 year after the onset of colitis [66] .
Although no standardised criteria for histological response in IBD patients following therapy are available, the presence of basal plasmacytosis in quiescent UC seems to be associated with a shorter disease relapse time [67] . It is also important to consider that an endoscopic description of MH does not necessarily imply histological healing of the mucosa [68] .
Effects of drugs on histological disease activity
In most of the available studies the evaluation of histological disease activity was not a treatment endpoint. Moreover, the endpoints for histological remission of disease for each patient were not defined, therefore data on this topic are relatively scarce.
Salicylates
In a double-blind, multicentre trial Kruis et al. [69] evaluated 3 different doses of 5-aminosalicylic acid (0.5 g three times/day, 1.0 g three times/day, and 1.5 g three times/day) in 321 active UC patients for 8 weeks. Histological improvement was defined as a reduction of the histological activity index (HI) by at least 1 point. Data analysis showed that the 3.0 g/day dose had a higher rate of endoscopic improvement (84%) as compared to the 1.5 g/day (53%) and 4.5 g/day (70%) doses, but the histological improvement rates were lower. The safety and efficacy of balsalazide (6.75 g daily), or sulfasalazine (3 g daily) were compared in an 8-week randomised, multicentre, double-blind, parallel group study that included 50 patients with mild to moderate UC [70] . The trial medication was the sole treatment and the efficacy was scored by symptom assessment, sigmoidoscopic appearance, and histology (rectal biopsies, performed at enrolment and at the final visit). Each biopsy was graded on a 4-point scale (normal to severe inflammation) and all the patients included in the study had at least mild inflammation at entry (58% severe inflammation). In this study, the inclusion of histology in the assessment of efficacy was meant to identify patients in whom clinical remission was associated with histological remission. After treatment, an improvement was observed in both groups; 61% of the patients taking balsalazide achieved clinical and sigmoidoscopic remission. Similarly, an improvement of histological grades was seen with both treatments and the number of patients with normal mucosa or minimal inflammation without active disease increased in both groups. In another study, Kruis et al. studied the efficacy and safety of 2 different treatment dosages (3 g once daily or 1 g three times a day) of mesalazine granules in 380 UC patients [71] . Endoscopy and histology were performed at baseline and the final visit (8 weeks), the total histological index being based on the most severely inflamed segment. Endoscopic remission was obtained in about 70% of the patients in both treatment groups, while histological remission was observed in 35% of patients in the once daily group and in 41% of those in the twice daily group. Endoscopy and histology revealed no statistically significant differences between the 2 dosing regimens. Prantera and colleagues evaluated the therapeutic response to slow-release mesalazine (MMx) compared with topical 5-ASA in 79 patients with active leftsided disease [72] . Endoscopic remission was achieved by 45% of the patients treated with MMx and by 37% of those treated with enemas. Histological remission (Floren score) [73] was obtained in only 15% of the patients treated with MMx and in 8% of the patients treated with enema. Malchow and colleagues investigated 264 patients with active distal UC, treated with 5-ASA foam or liquid enema [74] . After 4 weeks, in both treatment groups the overall remission rate was about 38%. Histological analysis showed an improvement in both treatment groups (46% remission in the foam group and 50% in the enema group).
Considering topical treatments, a trend in favour of mesalazine as compared to steroids is observed; 295 patients presenting with a relapse of distal UC were treated with 2 g mesalazine foam enema or 20 mg prednisolone foam enema [75] . After 4 weeks of treatment, clinical remission was achieved by 52% of mesalazine-treated patients and 31% of prednisolone-treated patients. Endoscopic remission was achieved in 40% of patients in the mesalazine group and 31% in the steroid group. Similarly, mesalazine induced histological remission in 27% of the patients whereas the same effect was induced in 21% of the steroid-treated patients.
Steroids
The capacity of corticosteroids to induce MH in UC patients is well recognised [76] . The seminal paper by Truelove [77] showed that hydrocortisone hemisuccinate sodium administered rectally induces rapid clinical remission in patients with mild to moderate UC. After 1 week of treatment patients showed a striking improvement in terms of endoscopic and histological variables. The steroid-treated group had a significantly better histological appearance after treatment as compared to baseline and to the placebo group.
Immunomodulators
Data from a few studies suggest that azathioprine causes a significant degree of endoscopic healing and histological improvement in the majority of CD patients. However, the rates of MH using azathioprine vary among studies, probably due to differences in the timing of endoscopy and the population considered. In an open label study, Sandborn et al. demonstrated, for the first time, that a loading dose of intravenous azathioprine induced complete endoscopic remission in 3 of 6 patients with active CD [78] .
In a subsequent study, D'Haens et al. evaluated MH using azathioprine in a cohort of 19 patients with recurrent postoperative CD of the neoterminal ileum [79] . At least 6 months after complete weaning from steroids, 15 patients (79%) achieved clinical remission; in this group colonoscopy showed complete macroscopic healing of the neoterminal ileum in 6 patients. Comparison of biopsy specimens taken before and after taking azathioprine showed persistent mucosal architectural changes, with a complete disappearance of the inflammatory infiltrate only in patients with complete macroscopic healing.
The same authors examined a series of consecutive CD patients with colitis and ileocolitis in clinical remission treated with azathioprine for at least 9 months, and compared disease parameters with pre-azathioprine data in the same patients [80] . The patients had been previously treated with steroids for at least 3 years and the ileocolonoscopy was performed less than 1 year before the start of azathioprine. In this study a global histological CD severity score was used [81] . This score combines active inflammatory changes (epithelial damage, infiltration of mononuclear cells, polymorphonuclear cells, presence of erosions and/or ulcers, granulomas) and chronic architectural changes, and includes a correction factor for the proportion of biopsy specimens affected by inflammation. The score ranged from 0 (normal) to 12 (severe inflammation in all biopsies). The purely "inflammatory activity score", which ranges from 0 to 7, was calculated based on the number of inflammatory cells in the epithelium and the lamina propria. Complete endoscopic healing was observed in the colon in 70% of the patients, and in 54% of the 13 patients with prior ileitis. Endoscopic healing was paralleled by a reduction in the histological score, mainly due to a reduction in the inflammatory infiltrate, but the latter was not always as "complete" as suggested by the endoscopy. In the patients with complete endoscopic healing, global histological scores decreased from 10 to 3; inflammatory scores decreased from 5 to 2. In patients without endoscopic healing during azathioprine therapy, no significant histological changes were observed. In patients with ileal healing, the microscopic changes were more complete and the global histological activity index decreased from a median of 7 to 2, whereas the inflammatory component of the score decreased from 2 to 0.
More recently, it has been demonstrated that early administration of azathioprine is effective not only in maintaining clinical remission but also in inducing higher rates of MH and histological remission than steroids (budesonide), in patients with steroiddependent inflammatory Crohn's ileocolitis or proximal colitis who had achieved clinical remission on conventional steroids [82] . In this comparative study the primary endpoint was the rate of MH and histological remission of CD, and the average histology score was calculated by dividing the sum of individual intestinal segmental scores by the number of intestinal segments explored. At the end of 1-year treatment, 32 patients in the azathioprine group and 25 in the budesonide group were in clinical remission; complete or nearly complete healing was achieved in 83% of azathioprinetreated patients compared with only 24% of budesonide-treated patients. In patients treated with azathioprine, MH was associated with a significant histological reduction of CD activity, although complete histological remission was not achieved. Moreover, the histology score fell significantly only in the azathioprine group, and much less improvement was observed in the budesonide group. Regarding the acute histological parameters (epithelial damage, acute inflammatory cell infiltrate of the lamina propria, erosions and/or ulcers), an improvement of all of them was observed regardless of disease location. The number of biopsies affected was significantly lower in azathioprine than budesonide-treated patients (32% vs. 82%). The only histological parameters unaffected by azathioprine were the glandular architecture and the presence of chronic inflammation.
Only a few studies have investigated the effect of methotrexate on mucosal healing in IBD patients. A pilot study that evaluated the effects of adding this agent to standard treatment (steroids, mesalazine) in 14 CD patients with refractory disease, elicited a normal histology after 12 weeks of treatment in 4 patients [83] . Another study, comparing the effect of methotrexate with that of azathioprine and infliximab in 40 CD patients, did not show significant differences between the 3 groups after 3 months of treatment [84] .
Biological therapy
The development of biological agents for the treatment of CD sparked interest in the MH field due to the potential alteration of the disease course. Endoscopic and histological response to infliximab was investigated in a multicentre, randomised, double-blind, and placebo-controlled trial including 30 patients with active CD [85] . After 4 weeks of intravenous administration of 5, 10, or 20 mg/kg of infliximab or placebo as a single infusion, the endoscopic improvement was significantly superior in infliximab-treated patients as compared to the placebo group. Histologically, a disappearance of the inflammatory infiltrate was observed only in infliximabtreated patients; however, cytoarchitectural changes persisted in most patients.
These data were confirmed by an immunohistological study conducted in 15 patients with steroid-refractory CD treated with a single infusion of infliximab (5-20 mg/kg); 5 patients were treated with placebo [86] . After 4 weeks of infliximab, but not after placebo, the total histological activity score was significantly reduced in both ileitis and colitis patients, and the total histological disease activity decreased considerably, mainly due to the decrease in the inflammatory activity scores (reduction in the number of neutrophils in the epithelium and lamina propria). Immunohistochemical staining showed a decrease of inflammatory reactions, and the number of lamina propria mononuclear cells showed a global reduction of CD4 and CD8 T lymphocytes and CD68 monocytes. In a small study of 10 CD patients, the use of etanercept (another anti-TNF␣ agent) did not improve histological variables after 2 weeks [87] .
Regarding biologicals, it is well known that anti-TNF␣ therapy can lead to MH in patients with UC [84, 85] , but to date histological data are limited. A small study investigating 9 moderate-severe UC patients treated for 10 weeks showed a significant decrease of the histological score only in responders (67% of the entire group); however, histological normalisation was observed in only 30% of these [88] . In another study, ultrastructural colonic features were studied in 7 UC patients before and after (2 weeks) infliximab treatment. After treatment, ultramicroscopic examination showed a morphological and functional improvement of the epithelial organelles, rich mucus secretion, and recovery of the chorionic components [89] .
Conclusion
MH is an important goal in CD and UC therapy, and is associated with a reduced disease progression and improved quality of life. Moreover, it is an important factor (especially since the advent of biological therapies) in the reduction of the risk of colorectal malignancies in UC [22] . Ileocolonoscopy has become the gold standard in the management of inflammatory bowel disease and can be used to support therapeutic decision-making. At present, the endoscopic definition of MH is considered to be the absence of all ulcerations and inflammation, even though the use of several different endoscopic scoring systems, with different cutoff values, leads to differences in MH rates. Identifying cutoff values to distinguish the endoscopic response to treatments should enable endoscopic scores to be used in clinical practice to evaluate MH as a parameter of remission or relapse.
In terms of future research, it is important to establish the value of endoscopy as a means of guiding therapeutic changes and decision-making, to continue or stop therapy, or to switch to another treatment. Endoscopic re-evaluation should be used to identify non-responder patients, in whom an increased dosage, anticipated administration, or use of other drugs should be attempted. Furthermore, to improve the follow-up of IBD patients, it should be established whether histology should be included in the definition of MH. Since ileocolonoscopy in CD evaluates only the lower gastrointestinal tract, wireless capsule endoscopy must be considered to assess MH in the upper gastrointestinal tract. Moreover, as shown in Table 2 , analysis of the published studies on biological agents demonstrates that different factors affect the rate of MH: (i) the definition of MH; (ii) the type of biological drug and other associated medications; (iii) the duration of treatment.
The timing of the endoscopic evaluation and a proper definition of MH need to be defined in prospective studies. To date, MH in IBD is still an underestimated issue [90] . Discrepancies between histological, endoscopic and clinical data exist, but are rarely assessed in therapeutic trials. This poses a problem, since normal clinical, serological and endoscopic findings are not indicative of histological absence of disease activity. Thus, it is important and advisable to plan future studies that also feature, as a key element, a comparison between endoscopic and histological variables.
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